Skip to content
Annika Bansal – Lifestyle
Author:
NanoViricides
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
May 19, 2026
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
May 15, 2026
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
May 11, 2026
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
May 4, 2026
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
April 21, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
April 7, 2026
←
Previous Page
1
2